Misplaced Euphoria – The Cannabis Industry Isn’t Crossing a Finish Line. It’s Becoming a Pawn in a Brand New Battle Line

The cannabis industry believes it is about to cross a finish line. In reality, it has just crossed a line.

State cannabis markets are no longer experiments. They’re mature revenue streams that prop up flagging state budgets in a declining economy. Many of the states that depend on cannabis revenue are the very same liberal states locked in heated battles with the Trump administration over other salient ideals.

Amid euphoria over potential rescheduling and long-awaited tax relief, cannabis operators are missing the elephant in the room. The states most willing to protect cannabis markets are the same states under federal budgetary and enforcement pressure, particularly around immigration and regulatory compliance.

Cannabis is not insulated from that conflict. It’s exposed by it.

The DoJ is Accused of Losing its Moral Compass

The Trump administration is now openly accused of selective targeting and enforcement along ideological lines. It is becoming increasingly obvious that political opposition makes states and individuals an enforcement target. This is a frightening precedent for vulnerable populations.

And nothing makes selective enforcement easier or more appealing than legal grey areas.

Cannabis operators are about to learn what it feels like to become unwitting participants in a soft civil war between state and federal governments. This is not a war fought with tanks or barricades. It’s fought through funding freezes, administrative choke points, and unprecedented jurisdictional erosion.

Cannabis Gets Caught in the Crossfire

An example of this jurisdictional erosion is the ever-increasing 287g program that’s encouraging state and federal enforcement cooperation on a massive scale. The recent immigration raid against Glass House is just one example of this federal and local cooperation.

For those who don’t know what the 287g program is, it’s an incentive for local governments to cooperate with ICE, via equitable sharing of seized assets, in the increasingly hostile battle over immigration enforcement.

We’ll discuss this more in later sections of this series, but for now, suffice it to say that local governments are being incentivised to allow the feds into areas of enforcement where they were previously barred by policies of non-interference or outright funding denial.

In this environment, cannabis is not merely an ideological target…it’s a nearly irresistible one.

READ MORE…

Why Trump’s EO on Rescheduling is a Red Herring

Against that backdrop, President Trump’s executive order directing the DEA to expedite cannabis rescheduling has been widely misread as a victory lap. Stocks surged. Headlines focused on historic progress and the promise of Section 280E relief. But the real question is not whether rescheduling will happen. It’s where the industry will stand once the high wears off.

First things first: cannabis has not been rescheduled yet. The rulemaking process remains vulnerable to defunding, delay, and legal challenge. In fact, the legal challenges are virtually guaranteed. The proposal itself acknowledges Congress’s ability to stall or derail implementation, and it preserves significant discretion for a resistant DEA. These caveats are not nefarious; they’re procedural. But they underscore a crucial point, that nothing about this process is settled, safe, or insulated from inevitable political interference.

Legal challenges are not hypothetical. They’ve been anticipated since Nebraska Attorney General Mike Hilgers organized a multistate opposition campaign against rescheduling. That pushback is unlikely to kill the process outright. However, it will shape it. Cannabis opponents have no incentive to block rescheduling entirely if they can instead control the regulatory terrain that follows.

And that’s where the real danger lies.

What Rescheduling Does, and Doesn’t Do for the Industry

Rescheduling doesn’t liberalise cannabis. It federalises it. It opens the door to regulatory capture by actors who already know how to navigate FDA approval pathways, federal supply chains, and national distribution. This consolidation path did not begin with this administration. It has been developing for years. The executive order merely accelerates it.

Strip away the rhetoric, and the EO has two practical objectives:

• First, to funnel cannabis into FDA-guided research and standards under an increasingly overwrought public-safety narrative.
• Second, to clamp down on hemp-derived products, particularly full-spectrum cannabinoids and THC ratios, under a unified federal framework. Together, these moves pave the way for pharmaceutical-style oversight of cannabis and beverage-style commercialisation of hemp. This should surprise no one. The 2018 Farm Bill deliberately created a temporary, under-standardised hemp market while deferring FDA authority. That limbo was never meant to last. It bought time, set the stage, and gave the industry the rope needed for it to hang itself…nothing more.

The intent was spelt out clearly in the HHS rescheduling analysis:

“Based on these diverse sources of marijuana, there is a lack of unified controls on cultivation and manufacturing, which raises concerns related to the safety, quality, and consistency of botanical substances…” (See page 22)

Once cannabis products are positioned as drugs, make health claims, and enter interstate commerce, FDA authority attaches. What’s changing? FDA’s enforcement authority is far less defined under Schedule 1.

These are conditions that rescheduling actively encourages. Enforcement doesn’t have to be universal to change the playing field. Compliance gravity alone creates the black hole that reshapes access to capital, insurance, banking, and distribution.

Not That Big Pharma Takeover Line Again…

Yes, this really is a Big Pharma and Big Alcohol moment, and the inflection point that activists have warned about for decades.

Pharmaceutical companies will finally receive a clear pathway to patented, clinical-trial-backed formulations. These will be isolates or synthetics that patients already reject, but Big Pharma believes that regulatory capture will tip the scales in their favor anyway. They wrongly believe prohibition is an actual deterrent to manufacture of a medication that literally grows on trees.

Big Alcohol is aiming for a compliant runway for low-dose cannabinoid beverages through existing retail and distribution infrastructure–although the FDA has already missed the congressional deadline to name specific cannabinoids in the plant and legally define what constitutes “a container.”

Legacy cannabis operators may believe they can secure footholds at the margins, but most are structurally behind firms that have spent decades mastering FDA processes or already control national shelf space.

How the Changing Enforcement Landscape Affects Cannabis

Meanwhile, state-based legacy markets grow more vulnerable, not less. Many operators assume that staying intrastate insulates them from federal pressure.

It does not.

States like Missouri that previously outright banned cooperation with federal authorities for cannabis enforcement have seen dozens of local jurisdictions pairing with ICE over immigration enforcement. These partnerships open up avenues of enforcement that were previously closed through DoJ policy or congressional funding bans.

The cannabis market isn’t just a symbol of bodily autonomy and personal freedom. It’s a lucrative market that states depend on to cover budget shortfalls. It’s also a juicy target for incentivised law enforcement that benefits from civil asset forfeiture.

Through 287g and other programs, local governments are now overriding decades-long state and federal non-interference policies that cannabis operators previously relied on. Meanwhile, income from cannabis taxes become a tempting federal choke point to further financially punish “sanctuary states” that resist this administration’s agenda.

We’re witnessing the beginning of a perfect storm, and the cannabis industry is one of several targets that lie at the center, and clearly the lowest hanging fruit. Why? Cannabis is:

• federally illegal,
• documentation-heavy,
• labor-exposed,
• politically stigmatised,
• revenue-critical to states

And again, to drive the point home, it’s a juicy target for incentivised law enforcement that benefits from civil asset forfeiture.

I’ve watched opponents chip away at progressive cannabis policy for three decades. This phase will be faster and more surgical than previous ones. We will see the obvious changes play out before election day.

Why? Largely because cannabis is an easy target in the ideological battle now playing out between states and the Fed. Also because there’s a flood of dark money from ideologues and opportunists alike funding this battle. So, in this series, I’ll lay out the existing hurdles rescheduling faces, the new enforcement tools that come into play when it finally passes, the changing enforcement landscape that is eroding the previous demilitarised zone between state and federal cannabis policy, and how, ultimately, 280E tax relief becomes completely irrelevant in our new normal.

Business of Cannabis will publish the next part of this series in the coming days…